What is Baxalta Price-to-Operating-Cash-Flow?
As of today (2024-05-06), Baxalta's share price is $46.02.
Baxalta's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2016 was $1.57. Hence, Baxalta's Price-to-Operating-Cash-Flow Ratio for today is 29.41.
The historical rank and industry rank for Baxalta's Price-to-Operating-Cash-Flow or its related term are showing as below:
Baxalta's Cash Flow from Operations per share for the
three
months ended in Mar. 2016 was $0.19.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2016 was $1.57.
Baxalta Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Baxalta's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Baxalta Price-to-Operating-Cash-Flow Chart
|
Baxalta Annual Data
|
|
Trend |
Dec12 |
Dec13 |
Dec14 |
Dec15 |
| Price-to-Operating-Cash-Flow |
|
- |
- |
- |
33.36 |
|
Baxalta Quarterly Data
|
|
Dec12 |
Dec13 |
Mar14 |
Jun14 |
Sep14 |
Dec14 |
Mar15 |
Jun15 |
Sep15 |
Dec15 |
Mar16 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
- |
16.12 |
17.71 |
33.36 |
25.81 |
Competitive Comparison of Baxalta's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, Baxalta's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Baxalta's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Baxalta's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Baxalta's Price-to-Operating-Cash-Flow falls into.
Baxalta Price-to-Operating-Cash-Flow Calculation
Baxalta's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 46.02 | / | 1.565 |
| = | 29.41 |
Baxalta's Share Price of today is $46.02.
Baxalta's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.57.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Baxalta (Baxalta) Business Description
Traded in Other Exchanges
N/A
Address
Baxalta Inc was incorporated on September 8, 2016. It is a biopharmaceutical company engaged in the field of unmet medical needs covering various diseases which includes haemophilia, immunology and oncology. The Company develops, manufactures and markets a diverse portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia. It also invests in emerging technology platforms, including gene therapy and biosimilars. Its competitors include Advate, Feiba, Gammagard. The Company is subject to rules and regulations put forth by the jurisdiction it operates in.
Executives
| Gail D Fosler |
director |
C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015 |
| John Glasspool |
officer: See Remarks |
C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015 |
| Dagmar Rosa-bjorkeson |
officer: EVP and President, Biosimilars |
C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015 |
| David D. Meek |
officer: EVP and President, Oncology |
3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906 |
| Karen Jean Ferrante |
director |
150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818 |
| Peter G Edwards |
officer: SVP and General Counsel |
C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015 |
| Robert J. Hombach |
officer: EVP. CFO and COO |
C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015 |
| Blake E Devitt |
director |
C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015 |
| Wayne T Hockmeyer |
director |
ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
| Anne-marie Law |
officer: EVP & Head of Human Resources |
C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015 |
| Stroucken Albert P L |
director |
BAXTER INTERNATIONAL INC., ONE BAXTER PARKWAY, DEERFIELD IL 60015 |
| Gavin James R Iii |
director |
BAXTER INTERNATIONAL INC, ONE BAXTER PARKWAY, DEERFIELD IL 60015 |
| John D Forsyth |
director |
C/O BAXTER INTERNATIONAL, ONE BAXTER PARKWAY, DEERFIELD IL 60015 |
| Ludwig Hantson |
director, officer: President and CEO |
C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510 |
| Francois Nader |
director |
550 HILLS DRIVE, BEDMINSTER NJ 07921 |
Baxalta (Baxalta) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BXLT has been successfully added to your